← Leaderboards
Kyle Matthew Kampman
University Of Pennsylvania
$31,481,891
Attributed
$53,755,121
Total exposure
18
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $21M · FY2005–25$25M$18.8M$12.5M$6.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$55,093,351 · 18
VA$0 · 1
By mechanism
UF1$13,263,199 · 1
U01$9,467,770 · 3
UH3$8,178,365 · 1
R01$6,216,610 · 3
U54$5,089,831 · 1
UG3$4,061,892 · 1
Top collaborators
- Anna Rose Childress8 shared
- Laura M Dember4 shared
- John T Farrar4 shared
- George E Woody4 shared
- Ashish Prakash Thakrar3 shared
- Hillary R Bogner2 shared
- Jesse Yenchih Hsu2 shared
- J Richard Landis2 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Anna Rose Childress$14,753,643
- George E Woody$40,983,108
- Richard C. Crist$940,547
- Ashish Prakash Thakrar$539,903
- Donna M Coviello$2,240,453
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsClinical TrialsAddictionRandomizedPennsylvaniaUniversitiesOutpatientsPlacebosBuprenorphineCocaineOpioidUrineNaltrexoneDoseRelapseOpioid Use DisorderCravingResponseAbstinenceBaseBrainInnovationMedicalDesign
Grant awards (58)
Combining Pregabalin with Lofexidine: Can it Increase the Success of Transition to Naltrexone?$2,584,873
UH3 · FY2025 · DA · contact PI
Psilocybin: Capturing brain mechanisms of motivation and neurocognition in individuals with opioid use disorder$472,087
R61 · FY2025 · DA
Rapid outpatient low-dose initiation of buprenorphine for individuals with OUD using fentanyl$230,000
R34 · FY2025 · DA · contact PI
Combining Pregabalin with Lofexidine: Can it Increase the Success of Transition to Naltrexone?$2,708,839
UH3 · FY2024 · DA · contact PI
The Whole Health Study: Collaborative Care for OUD and Mental Health Conditions$2,065,898
UF1 · FY2024 · MH
Psilocybin: Capturing brain mechanisms of motivation and neurocognition in individuals with opioid use disorder$495,024
R61 · FY2024 · DA
A Clinical Laboratory with Integrated Neuroscience (CLIN) for Early Evaluation of Medications for Substance Use Disorders$493,985
UG1 · FY2024 · DA · contact PI
Rapid outpatient low-dose initiation of buprenorphine for individuals with OUD using fentanyl$227,250
R34 · FY2024 · DA · contact PI
UPENN Scientific and Data Research Center for the HOPE Consortium to Reduce Pain and Opioid Use in Hemodialysis$1
U01 · FY2024 · DK
Combining Pregabalin with Lofexidine: Can it Increase the Success of Transition to Naltrexone?$2,884,653
UH3 · FY2023 · DA · contact PI
A Clinical Laboratory with Integrated Neuroscience (CLIN) for Early Evaluation of Medications for Substance Use Disorders$650,165
UG1 · FY2023 · DA · contact PI
Rapid outpatient low-dose initiation of buprenorphine for individuals with OUD using fentanyl$232,750
R34 · FY2023 · DA · contact PI
A Clinical Laboratory with Integrated Neuroscience (CLIN) for Early Evaluation of Medications for Substance Use Disorders$727,881
UG1 · FY2022 · DA · contact PI
A Clinical Laboratory with Integrated Neuroscience (CLIN) for Early Evaluation of Medications for Substance Use Disorders$520,270
UG1 · FY2021 · DA · contact PI
UPENN Scientific and Data Research Center for the HOPE Consortium to Reduce Pain and Opioid Use in HemodialysisÂ$366,272
U01 · FY2021 · DK
A Clinical Laboratory with Integrated Neuroscience (CLIN) for Early Evaluation of Medications for Substance Use Disorders$165,354
UG1 · FY2021 · DA · contact PI
Pharmacogenetic Study of Opioid Agonist Treatments in MVP$0
I01 · FY2021 · VA · contact PI
UPENN Scientific and Data Research Center for the HOPE Consortium to Reduce Pain and Opioid Use in HemodialysisÃÂÃÂÃÂÃÂ$720,000
U01 · FY2020 · DK
A Clinical Laboratory with Integrated Neuroscience (CLIN) for Early Evaluation of Medications for Substance Use Disorders$529,915
UG1 · FY2020 · DA · contact PI
Remote observed dosing to improve Suboxone compliance in clinical practice$241,500
U34 · FY2020 · DA · contact PI
The Whole Health Study: Collaborative Care for OUD and Mental Health Conditions$11,197,301
UF1 · FY2019 · MH
UPENN Scientific and Data Research Center for the HOPE Consortium to Reduce Pain and Opioid Use in Hemodialysis$5,498,565
U01 · FY2019 · DK
Combining Pregabalin with Lofexidine: Can it Increase the Success of Transition to Naltrexone?$4,061,892
UG3 · FY2019 · DA · contact PI
Remote observed dosing to improve Suboxone compliance in clinical practice$241,500
U34 · FY2019 · DA · contact PI
Pharmacogenetic Study of Opioid Agonist Treatments in MVP$0
I01 · FY2019 · VA · contact PI
Center for the Development of Novel Medications for Cocaine Dependence$961,502
U54 · FY2018 · DA · contact PI
Remote observed dosing to improve Suboxone compliance in clinical practice$241,500
U34 · FY2018 · DA · contact PI
Center for the Development of Novel Medications for Cocaine Dependence$1,001,222
U54 · FY2017 · DA · contact PI
Center for the Development of Novel Medications for Cocaine Dependence$1,017,927
U54 · FY2016 · DA · contact PI
Varenicline for the treatment of cocaine dependence: Phase II$556,118
U01 · FY2016 · DA · contact PI
Center for the Development of Novel Medications for Cocaine Dependence$1,020,281
U54 · FY2015 · DA · contact PI
2/2 Multicenter trial of combined pharmacotherapy to treat cocaine dependence$763,753
U01 · FY2015 · DA · contact PI
Center for the Development of Novel Medications for Cocaine Dependence$1,088,899
U54 · FY2014 · DA · contact PI
2/2 Multicenter trial of combined pharmacotherapy to treat cocaine dependence$775,384
U01 · FY2014 · DA · contact PI
Innovative Approaches for Cocaine Pharmacotherapy$1,338,230
P50 · FY2013 · DA · contact PI
2/2 Multicenter trial of combined pharmacotherapy to treat cocaine dependence$787,677
U01 · FY2013 · DA · contact PI
Multisite Controlled Trial of Cocaine Vaccine (4 of 6) Philadelphia Treatment Sit$335,525
R01 · FY2012 · DA · contact PI
Quetiapine for the treatment of Type A and Type B alcoholism$496,350
R01 · FY2011 · AA · contact PI
Multisite Controlled Trial of Cocaine Vaccine (4 of 6) Philadelphia Treatment Sit$378,118
R01 · FY2011 · DA · contact PI
Multisite Controlled Trial of Cocaine Vaccine (4 of 6) Philadelphia Treatment Sit$82,960
R01 · FY2011 · DA · contact PI
Quetiapine for the treatment of Type A and Type B alcoholism$515,381
R01 · FY2010 · AA · contact PI
Quetiapine for the treatment of Type A and Type B alcoholism$529,995
R01 · FY2009 · AA · contact PI
Quetiapine for the treatment of Type A and Type B alcoholism$520,268
R01 · FY2008 · AA · contact PI
Topiramate for alcohol and cocaine dependence$374,581
R01 · FY2008 · AA · contact PI
Multisite Controlled Trial of Cocaine Vaccine (4 of 6) Philadelphia Treatment Sit$354,375
R01 · FY2008 · DA · contact PI
Naltrexone & Topiramate Combined for the Treatment of Cocaine and Alcohol Depende$239,895
P50 · FY2008 · DA · contact PI
Quetiapine for the treatment of Type A and Type B alcoholism$521,974
R01 · FY2007 · AA · contact PI
Topiramate for alcohol and cocaine dependence$519,405
R01 · FY2007 · AA · contact PI
Naltrexone & Topiramate Combined for the Treatment of Cocaine and Alcohol Depende$252,729
P50 · FY2007 · DA · contact PI
Topiramate for alcohol and cocaine dependence$549,223
R01 · FY2006 · AA · contact PI
Topiramate for the Treatment of Cocaine and Alcohol Dependence$62,592
P50 · FY2006 · DA · contact PI
Topiramate for alcohol and cocaine dependence$551,426
R01 · FY2005 · AA
Topiramate for the Treatment of Cocaine and Alcohol Dependence$356,283
P50 · FY2005 · DA
Topiramate for alcohol and cocaine dependence$487,029
R01 · FY2004 · AA
Topiramate for the Treatment of Cocaine and Alcohol Dependence$353,802
P50 · FY2004 · DA
Amantadine and Propranolol for Cocaine Dependence$165,355
P50 · FY2002 · DA
Amantadine and Propranolol for Cocaine Dependence$165,355
P50 · FY2001 · DA
Amantadine and Propranolol for Cocaine Dependence$412,262
P50 · FY2000 · DA